Evidence map›Paper›PMID 40483636›Full record

ArticleFuture oncology (London, England)2025

Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC.

Yi-Chun Lai, Cheng-Yu Chang, Yu-Feng Wei, Chung-Yu Chen, Shih-Chieh Chang

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yi-Chun LaiDivision of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan.
Cheng-Yu ChangDivision of Chest Medicine, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Yu-Feng WeiDepartment of Internal Medicine, E-Da Cancer Hospital, I-Shou University, Kaohsiung, Taiwan.
Chung-Yu ChenDepartment of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan.
Shih-Chieh ChangDivision of Chest Medicine, Department of Internal Medicine, National Yang Ming Chiao Tung University Hospital, Yi-Lan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe clinical characteristics and outcomes of younger versus older patients with EGFR-mutated advanced NSCLC undergoing first-line EGFR-TKI treatment remain underexplored.

methodsThis multicenter, retrospective study analyzed patients treated between 2010 and 2019. Univariate and multivariate analyses identified factors associated with outcomes.

resultsAmong 235 patients, 38 were under 50 years and 197 over 65 years. Median progression-free survival (PFS) was 21.1 months in younger patients and 15.6 months in older patients (

conclusionYounger patients receiving afatinib or erlotinib showed better outcomes. For older patients, clinical factors such as functional status and body weight strongly influenced survival.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsMutationProtein Kinase InhibitorsAdultAfatinibAgedAged, 80 and overAge FactorsErbB ReceptorsErlotinib HydrochlorideFemaleHumansMaleMiddle AgedPrognosisAfatinibEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideProtein Kinase Inhibitorsafatinib and erlotinibECOG performance statusEGFRmulticenter studyNSCLCTaiwanTKIyoung age

Identifiers

PMID40483636
PMCPMC12239823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.